Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "NHA"

1853 News Found

GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
News | August 02, 2024

GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr

Strong topline growth driven by solid performance across key brands.


Lupin receives approval from USFDA for Emtricitabine and Tenofovir Alafenamide Tablets
Drug Approval | August 01, 2024

Lupin receives approval from USFDA for Emtricitabine and Tenofovir Alafenamide Tablets

This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries


DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control
Policy | August 01, 2024

DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control

More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options


Barentz acquires Anshul Life Sciences to strengthen India portfolio
News | July 31, 2024

Barentz acquires Anshul Life Sciences to strengthen India portfolio

The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform


Steps taken by India for preparedness against future pandemics
Policy | July 29, 2024

Steps taken by India for preparedness against future pandemics

Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting


Cupid widens e-Commerce presence on leading Indian platforms
News | July 26, 2024

Cupid widens e-Commerce presence on leading Indian platforms

This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide


Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’
Drug Approval | July 26, 2024

Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’

Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials


Piramal Pharma Q1 FY25 net loss narrows
News | July 26, 2024

Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24